Screener
Allogene Therapeutics ALLO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's shares (diluted)?
- Allogene Therapeutics (ALLO) reported shares (diluted) of 240.3M in Q1 2026.
- How has Allogene Therapeutics's shares (diluted) changed year-over-year?
- Allogene Therapeutics's shares (diluted) increased by 11.6% year-over-year, from 215.4M to 240.3M.
- What is the long-term trend for Allogene Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Allogene Therapeutics's shares (diluted) has grown at a 12.9% compound annual growth rate (CAGR), from 539.8M to 876.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Allogene Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude